MedTrace Logo

Schistosoma Mansoni in Mwanza Region, Tanzania

NCT02162875 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37500

Last updated 2017-02-10

No results posted yet for this study

Summary

The objective of this study is to determine the strategy for mass drug administration (MDA) which provides the greatest reductions in prevalence and intensity of Schistosoma mansoni in school-aged children after 4 years of intervention.

Conditions

  • Schistosoma Mansoni

Interventions

DRUG

Praziquantel

Six different treatment strategies with praziquantel

Sponsors & Collaborators

  • DBL -Institute for Health Research and Development

    lead OTHER

Principal Investigators

  • Safari Kinung'hi, PhD · National Institute for Medical Research, Mwanza Research Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Tanzania

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02162875 on ClinicalTrials.gov